Sumitomo Riko Co. Ltd. (TYO:5191) recently announced that it has jointly developed a new microfluidic device in conjunction with Lilac Pharma Inc., a pharmaceutical venture from Hokkaido University. Plans are to begin pre-orders this winter for the new device, which is used to manufacture lipid nanoparticles. The microfluidic device consists of two primary components: a microfluidic chip for creating the…
Please subscribe to read the full story.Subscribe
Already a member? Log in here
